Funder: Pfizer Inc.
Due Dates: March 27, 2026 (Full application) | November 15, 2026 (Documentation for selected projects)
Funding Amounts: Up to EUR 50,000 per project; total program budget EUR 150,000; max project length 1 year
Summary: Supports research and quality improvement projects to enhance care for HR+/HER2- metastatic breast cancer patients in Italy, focusing on elderly and complex cases using real-world, patient-centered strategies.
Key Information: Applicants must be based in Italy; only organizations are eligible, not individuals.